Fact CheckerSign in

NCT04875234Not yet recruiting

Vision Improvement for Legally Blind Dry AMD Patients

Vision Improvement for Legally Blind Dry Age-Related Macular Degeneration Patients

Source: ClinicalTrials.gov · Last updated 22 Mar 2023 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This retrospective observational study is intended to assess the feasibility of using a nonsignificant risk device for vision improvement for legally blind dry AMD patients.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
40 (estimated)
First submitted
3 May 2021
Start date
Jan 2024
Primary completion date
Jul 2025
Lead sponsor
Optimal Acuity Corporation
NCT number
NCT04875234

What you commit to

  • Study type: Observational
  • Planned participants: 40
  • From Jan 2024 to the primary completion date, Jul 2025
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Presence of a visually significant posterior capsule opacity if prior cataract surgery has been performed in the study eye
  • Previous corneal surgery in the study eye

Other illness

  • Any visually significant disease process in any ocular structure other than AMD that would affect vision in the study eye
  • Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or may confound the outcome of the study

Other

  • Visually significant cataract in the study eye

Criteria the registry did not label

  • IInclusion Criteria:
  • Male or Female
  • Any race
  • Patient is at least 50 years old.
  • Patient must have dry AMD in the study eye.
  • Patient is legally blind due to AMD - i.e., has corrected distance visual acuity (CDVA) of 20/125 or worse (45 letters; logMAR ≥ 0.80) in the study eye.
  • Patient has normal corneal surface topography on videokeratography (i.e., without distorted or unclear corneal mires).
  • Patient is not a contact lens wearer.
  • Patient is willing and able to comply with all examinations.
  • Patient must be competent to sign an informed consent form before study entry.

Age in the registry: 50 years to 100 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.